Shift represents growing understanding of value of genetic testing for cancers. Find out who is receiving the test and why.
A KPMG-Leavitt Partners report shows Medicare Advantage and Managed Medicaid are on slightly different trajectories. Expert Ash Shehata shares his predictions for both markets.
The impact of VBRs on outcomes, VBRs versus other healthcare reimbursement initiatives, and VBR successes and failures. Pfizer’s Robert Popovian, PharmD, weighs in.
From State-led programs to innovative pharmacist-hospital partnerships, these programs are fighting to quell the epidemic.
How are generic prices changing, how will biosimilars impact costs, and what changes out of Washington should healthcare executives watch? Economics guru Joe Fuhr weighs in.
CMS unveiled a voluntary episode bundled payment model, Bundled Payments for Care Improvement Advanced (BPCI Advanced). Here’s six things experts want you to know
Willis Towers Watson research finds a dramatic increase among employers seeking to differentiate their health and well-being programs for competitive advantage.
With influenza activity increasing sharply, here’s how healthcare executives can determine which health plan members are at risk for the flu.
Trump’s new proposal would broaden access to association health plans. Here’s six things to know.
A new report from Cardinal Health Specialty Solutions gives behind-the-scenes perspectives from oncologists about CAR-T cell therapies, biosimilars and AML therapies (or genomic medicines)